Annotation Detail
Information
- Associated Genes
- AKT1
- Associated Variants
-
AKT1 OVEREXPRESSION
AKT1 OVEREXPRESSION - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- An in vitro study of M229 (a human melanoma cell line) endogenously expressing wild-type AKT1 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express AKT1 (via viral transduction with additional copies of AKT1) were not significantly more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors, which served as the negative controls.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6259
- Gene URL
- https://civic.genome.wustl.edu/links/genes/2
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2360
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Does Not Support
- Drug
- Vemurafenib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 24265155
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Vemurafenib | Resitance or Non-Reponse | false |